SecBot SecBot
144 ·Filed Jun 24, 2026

BBIO

BridgeBio Pharma, Inc.
NEUTRAL
Impact 2/10
Horizondays Processed4mo ago SEC0001950047-26-006457
Form 144, notice of proposed sale of securities
Actionable Insight • Neutral

This is a routine, pre-planned insider sale under a 10b5-1 plan. The small size and pre-arranged nature suggest no negative signal. Monitor for any acceleration of insider selling or unexpected Form 4 filings that could indicate a change in sentiment.

DirectionNeutral
Confidencehigh
Horizondays

How the stock moved after the report

NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60
Entry
$69.69
T+0 close · Jun 24, 2026 · via day close
Latest settled
−4.42%
T+60 · $66.61
Vs SPY
−8.15%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Jun 25 $69.69entry
  2. T+1 · 5mo ago +0.79%α +1.51% · $70.24
  3. T+5 · 5mo ago +6.93%α +5.37% · $74.52
  4. T+20 · 4mo ago +19.00%α +18.47% · $82.93
  5. T+60 · 8w ago −4.42%α −8.15% · $66.61
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

BridgeBio Pharma director Randal Scott filed a Form 144 notice of intent to sell 2,196 shares of common stock, with an estimated aggregate market value of approximately $150,711. The shares were acquired via restricted stock units that vested on June 20, 2026. The sale is being conducted under a Rule 10b5-1 trading plan established on June 27, 2025, which mitigates concerns about opportunistic timing. The proposed sale represents a de minimis portion of Scott's holdings relative to the company's $13.6B market cap and is consistent with routine insider diversification.

Key Facts

  • Director Randal Scott filed Form 144 to sell 2,196 shares of BBIO common stock.
  • Estimated aggregate market value of the proposed sale is approximately $150,711.
  • Shares were acquired through restricted stock units that vested on June 20, 2026.
  • Sale is being executed under a Rule 10b5-1 trading plan dated June 27, 2025.
  • The proposed sale represents less than 0.001% of BBIO's $13.6B market capitalization.
  • Recent insider activity (30d) shows 3 sells totaling $2.9M, indicating ongoing but modest insider selling.

Financial Impact

Proposed sale of 2,196 shares valued at ~$150,711, immaterial relative to $13.6B market cap.

insider holdingsdilution

Risk Factors

  • Insider selling pattern could accelerate if additional Form 144s or Form 4s are filed by other executives.
  • The 10b5-1 plan was established nearly a year ago, so the sale is not reactive to current fundamentals.

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
93% bullish (29 analysts)

Investment Themes

Documents Analyzed

This report is based on 3 SEC documents filed with EDGAR.

DocumentAccession Number
144 Filing (Primary)0001950047-26-006457
Document: 0001950047-26-006457-index.html0001950047-26-006457
Document: 0001950047-26-006457.txt0001950047-26-006457

Track record

38 reports on BBIO

Performance horizon

10 of 13 bullish or bearish reports moved the stock their way by T+20. Best: +26.76% at T+60 after the May 11, 2026 report. 14 of 15 went positive at some point.

Filters
  1. Nov 12, 20264d ago SC 13G/A Neutral 3/10 Entry $78.17 Now $78.30 +0.17% settles Dec 11
  2. Nov 9, 20267d ago Institutional Cluster Bullish 4/10 Entry $77.93 Now $78.30 +0.47% settles Dec 8
  3. Nov 6, 202610d ago Press Release Neutral 2/10 Entry $77.93 Now $78.30 +0.47% settles Dec 8
  4. Oct 29, 202618d ago 8-K Bullish 6/10 No price data
  5. Oct 29, 202618d ago Press Release Bullish 6/10 Entry $74.95 Now $78.30 +4.47% settles Nov 30
  6. Oct 27, 202620d ago SC 13G Neutral 3/10 Entry $70.82 Now $78.30 +10.56% settles Nov 25
  7. Oct 22, 202625d ago Press Release Neutral 1/10 Entry $68.12 Now $78.30 +14.94% settles Nov 19
  8. Oct 13, 20264w ago 8-K Bullish 7/10 Entry $63.30 to $78.67 Now $78.30 +23.70% ▲ +24.28% +27.89% vs SPY
  9. Oct 6, 20265w ago Press Release Bullish 7/10 Entry $66.96 to $74.03 Now $78.30 +16.94% ▲ +10.56% +13.73% vs SPY
  10. Oct 5, 20266w ago Press Release Neutral 2/10 Entry $66.96 to $74.03 Now $78.30 +16.94% ▲ +10.56% +13.73% vs SPY
Showing 10 of 38

US Market Status

Market Closed · Opens Wed (12h 12m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Jun 24, 2026